

### EXCLUSION CRITERIA

History of Candida Infection (Consult ID)  
Concomitant bacteremia or meningitis  
> 48 Weeks PMA  
< 7 days of age

## UTI Management Pathway (Neonatal) Evidence Based Outcome Center

### GUIDELINE INCLUSION CRITERIA

Infants <48 weeks PMA and greater than 7 days of life with Urinary Tract Infection present as defined by:  
>50,000 CFU/mL in catheter obtained specimen

- Alter antibiotic therapy based on culture-specific antimicrobial susceptibility
- Recommend treatment duration: 7 days if uncomplicated, 10 days if complicated **1**
- Consider transition to oral therapy if term (by PMA), once sensitivities completed
- DO NOT repeat urine culture for test of cure UNLESS candida or ESBL **1**

Obtain renal and bladder ultrasound (RBUS) following UTI treatment completion\*

\*If fever persists >48 hrs after start of antibiotics or unusually severe clinical illness, obtain RBUS sooner

Are any of the following present?

- Atypical pathogen
- Family history of Vesicoureteral Reflux (VUR) or Congenital anomalies of kidney and urinary tract (CAKUT)
- Complex clinical course
- ANY prior UTI

Yes

No

- Obtain VUCG  
- Obtain Renal Functional Panel  
- Consult urology  
- Consider nephrology consult

Is RBUS Normal?

No

Yes

- Complete antibiotic course **2**  
- No further evaluation is necessary

### Definitions:

**Definition of UTI:** > 50,000 CFU/mL in a catheter obtained specimen.

**Complicated UTI** – Functional or anatomic abnormality of the urinary tract, an indwelling urinary catheter, recent urinary tract instrumentation, recent antibiotic use, or immunosuppression.

**ESBL** – Bacteria with particular resistance to Penicillins

**Documentation:** Document diagnosis in Compass and BabySteps. Include date of diagnosis, antibiotic therapy, any associated imaging, and any associated consultations.

\* If fever persists >48 hrs after start of antibiotics or unusually severe clinical illness, obtain RBUS sooner.

**1**

### Medication Dosages:

- IV Cefazolin 50 mg/kg/day divided q8h
- PO Cephalexin
  - ≤ 28 days of life: 75 mg/kg/day divided q8h
  - ≥ 29 days of life: 100 mg/kg/day divided q6h

**2**

# UTI Management Pathway (Neonatal)

## Evidence Based Outcome Center



Physician Lead: Charlene Bultmann, DO

### Revision History

Date Approved: September 2024  
Next Review Date: September 2028  
Revision History: September 2024 – New Guideline Published to DCMC EBOC site

### EBOC Team:

Charlene (Charli) Bultmann, DO  
Lexi Wilson, PharmD  
Maggie Benton, PharmD  
Carmen Garudo, EBOC PM

### EBOC Leadership Team:

Sarmistha Hauger, MD  
Patty Click, RN  
Sheryl Yanger, MD  
Melissa Cossey, MD  
Tory Meyer, MD  
Nilda Garcia, MD  
Meena Iyer, MD  
Amanda Puro, MD  
Lynsey Vaughan, MD

**LEGAL DISCLAIMER:** The information provided by Dell Children’s Medical Center (DCMC), including but not limited to Clinical Pathways and Guidelines, protocols and outcome data, (collectively the "Information") is presented for the purpose of educating patients and providers on various medical treatment and management. The Information should not be relied upon as complete or accurate; nor should it be relied on to suggest a course of treatment for a particular patient. The Clinical Pathways and Guidelines are intended to assist physicians and other health care providers in clinical decision-making by describing a range of generally acceptable approaches for the diagnosis, management, or prevention of specific diseases or conditions. These guidelines should not be considered inclusive of all proper methods of care or exclusive of other methods of care reasonably directed at obtaining the same results. The ultimate judgment regarding care of a particular patient must be made by the physician in light of the individual circumstances presented by the patient. DCMC shall not be liable for direct, indirect, special, incidental or consequential damages related to the user’s decision to use this information contained herein.





References:

Tej K. Mattoo, Nader Shaikh, Caleb P. Nelson; Contemporary Management of Urinary Tract Infection in Children. *Pediatrics* February 2021; 147 (2): e2020012138. 10.1542/peds.2020-012138.

Pauchard JY, Chehade H, Kies CZ, Girardin E, Cachat F, Gehri M. Avoidance of voiding cystourethrography in infants younger than 3 months with Escherichia coli urinary tract infection and normal renal ultrasound. *Arch Dis Child*. 2017;102(9):804–808

Garcia-Roig M , Travers C , McCracken CE , Kirsch AJ . National trends in the management of primary vesicoureteral reflux in children. *J Urol*. 2018;199(1):287–293.

Bahat H , Ben-Ari M , Ziv-Baran T , Neheman A , Youngster I , Goldman M . Predictors of grade 3-5 vesicoureteral reflux in infants  $\leq$  2 months of age with pyelonephritis. *Pediatr Nephrol*. 2019;34(5):907–915.

Roberts KB ; Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management . Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. *Pediatrics*. 2011;128(3):595–610

